InvestorsHub Logo
Followers 10
Posts 469
Boards Moderated 0
Alias Born 08/02/2012

Re: foxwoodsfan post# 1819

Friday, 09/20/2013 9:04:03 AM

Friday, September 20, 2013 9:04:03 AM

Post# of 3057
Prosensa's data was released, which was that they did not meet their Phase III primary end point for their drug drisapersen. It was suspected that very good Prosensa (RNA) Phase III news or very bad Phase III news would be bad for SRPT.

Good RNA PhIII data would be bad for SRPT for the obvious reasons.
Bad RNA PHIII data would cast doubt on axon-skipping technology and the use of dystrophin as a clinical surrogate.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRPT News